Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021

Tuesday, June 6, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 5, 2017 /PRNewswire/ -- About Hospital Acquired Pneumonia (HAP) DrugsHAP is a type of pneumonia that

is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and
mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.Read the full report: http://www.reportlinker.com/p04921224/Global-Hospital-acquired-Pneumonia-HAP-Drugs-Market.htmlTechnavio's analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.Covered in this reportThe report covers the present scenario and the growth prospects of the global hospital acquired pneumonia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The market is divided into the following segments based on geography:• Americas• APAC• EMEATechnavio's report, Global Hospital Acquired Pneumonia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors• GlaxoSmithKline• Merck• Novartis• PfizerOther prominent vendors• Arsanis• AstraZeneca• Combioxin• Mylan• Shinogi• Sun Pharmaceutical Industries• Teva Pharmaceutical • The Medicines Company• Theravance BiopharmaMarket driver• Unmet demand due to lack of available treatment for MDR microorganisms• For a full, detailed list, view our report Market challenge• Growing cases of MDR microorganisms• For a full, detailed list, view our report Market trend• Combination therapy for the treatment of HAP• For a full, detailed list, view our report Key questions answered in this report• What will the market size be in 2021 and what will the growth rate be?• What are the key market trends?• What is driving this market?• What are the challenges to market growth?• Who are the key vendors in this market space?• What are the market opportunities and threats faced by the key vendors?• What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.Read the full report: http://www.reportlinker.com/p04921224/Global-Hospital-acquired-Pneumonia-HAP-Drugs-Market.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-hospital-acquired-pneumonia-hap-drugs-market-2017-2021-300468814.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook